Open access · CC-BY
via OpenAlex
Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Fernando Laso-García, Luke Diekhorst, Mari Carmen Gómez-de Frutos, Laura Otero‐Ortega, Blanca Fuentes, Gerardo Ruiz Ares, Exuperio Díez‐Tejedor, María Gutiérrez‐Fernández
Frontiers in Neurology · 2019 · ▲ 23 citations
Abstract
Stroke is a major health problem worldwide. It has been estimated that 90% of the population attributable risk of stroke is due to risk factors such as aging, hypertension, hyperglycemia, diabetes mellitus and obesity, among others. However, most animal models of stroke use predominantly healthy and young animals. These models ignore the main comorbidities associated with cerebrovascular disease, which could be one explanation for the unsuccessful bench-to-bedside translation of protective and regenerative strategies by not taking the patient's situation into account. This lack of success makes it important to incorporate comorbidities into animal models of stroke in order to study the effects of the various therapeutic strategies tested. Regarding cell therapy, the administration of stem cells in the acute and chronic phases has been shown to be safe and effective in experimental animal models of stroke. This review aims to show the results of studies with promising new therapeutic strategies such as mesenchymal stem cells, which are being tested in preclinical models of stroke associated with comorbidities and in elderly animals.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fneur.2019.00332
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
Laso-García, F., Diekhorst, L., Frutos, M.C.G., Otero‐Ortega, L., Fuentes, B., Ares, G.R., Díez‐Tejedor, E., & Gutiérrez‐Fernández, M. (2019). Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research. <em>Frontiers in Neurology</em>. https://doi.org/10.3389/fneur.2019.00332
Vancouver
Laso-García F, Diekhorst L, Frutos MCG, Otero‐Ortega L, Fuentes B, Ares GR, et al. Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research. Frontiers in Neurology. 2019. doi:10.3389/fneur.2019.00332.
BibTeX
@article{fernando2019CellBa,
title = {Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research},
author = {Fernando Laso-García and Luke Diekhorst and Mari Carmen Gómez-de Frutos and Laura Otero‐Ortega and Blanca Fuentes and Gerardo Ruiz Ares and Exuperio Díez‐Tejedor and María Gutiérrez‐Fernández},
journal = {Frontiers in Neurology},
year = {2019},
doi = {10.3389/fneur.2019.00332},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Springer eBooks 2016
Citation only
Mesenchymal Stem Cells for Stroke Therapy
World Journal of Experimental Medicine 2024
Open access · CC-BY
Anti-aging based on stem cell therapy: A scoping review
Critical Reviews in Biomedical Engineering 2012
Preprint · OA
Bone Tissue Engineering: Recent Advances and Challenges
International Journal of Molecular Sciences 2021
Open access · CC-BY
Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis
Zhonghua shiyan yanke zazhi 2019
Citation only
The research status and the limitations of mesenchymal stem cell-based therapies in age-related macular degeneration
Stem Cells 2019
Preprint · OA